MRG003 for head and neck cancer after prior treatments
Treatments studied
Part of Cancer clinical trials.
This trial tests MRG003, a cancer medicine, in people with recurrent or metastatic squamous cell carcinoma of the head and neck who have already tried and had trouble with standard treatments like platinum and anti–PD-1 therapy. It looks at whether the treatment can shrink the cancer and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell cancer in the head and neck that cannot be removed by surgery and has returned or spread
- Your cancer has already been treated and did not respond to platinum chemotherapy and/or anti–PD-1 therapy
- You have at least one measurable tumor spot doctors can track on scans
- You are expected to live at least 3 months and are well enough to do daily activities (ECOG 0 or 1)
- Blood counts, organ function, and blood clotting labs must be in acceptable ranges
- If you can become pregnant: your pregnancy test is negative and you use effective birth control during treatment and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (MRG003 with or without putrelimab) for people with advanced salivary gland cancer that has EGFR protein. It aims to see if the treatment is safe and helps shrink tumors.
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
This trial tests two drugs together: MRG003 (a targeted therapy that delivers chemo directly to EGFR-positive cancer cells) and pucotenlimab (an immunotherapy that helps your immune system attack the cancer). It is for people with a rare and aggressive thyroid cancer (ATC or PDTC) whose tumors have the EGFR protein and have grown despite previous treatment.
This trial tests a new drug called MRG004A (plus best supportive care) against a placebo (plus best supportive care) for people with advanced pancreatic cancer who have already tried chemotherapy. The goal is to see if MRG004A can help shrink or slow the cancer.
This trial tests a combination of two drugs (MRG003 and Toripalimab) given before surgery to shrink head and neck cancer tumors. It's for people with a specific type of cancer that hasn't been treated before and is PD-L1 positive.
This trial tests a combination of two targeted drugs for advanced head and neck cancer that has not responded to standard treatments. It specifically includes patients whose tumors have a change in the CDKN2A gene.
Hear when a new Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.